• 2.5mg/0.5mL
• 5mg/0.5mL
• 7.5mg/0.5mL
• 10mg/0.5mL
• 12.5mg/0.5mL
• 15mg/0.5mL

Tirzepatide

Tiezepatide

On the basis of findings in rats and mice, may cause thyroid C-cell tumors, including MTC, in humans; human relevance of tirzepatide-induced rodent thyroid C-cell tumors has not been determined

Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, observed in patients treated with GLP-1 receptor agonists; after initiating, monitor for signs and symptoms of pancreatitis (eg, persistent severe abdominal pain, which sometimes radiates to the back and may or may not be accompanied by vomiting); if pancreatitis suspected, discontinue and do not restart if confirmed

Rapid improvement in glucose control associated with temporary worsening of diabetic retinopathy; tirzepatide has not been studied in patients with nonproliferative diabetic retinopathy requiring acute therapy, proliferative diabetic retinopathy, or diabetic macular edema; monitor patients with a history of diabetic retinopathy

Gastrointestinal (GI) adverse reactions, sometimes severe, reported; has not been studied in patients with severe GI disease, including severe gastroparesis, and is not recommended in these patients

Acute gallbladder disease (eg, cholelithiasis, cholecystitis) reported in GLP-1 receptor agonist trials and postmarketing surveillance; if suspected, gallbladder studies and appropriate clinical follow-up are indicated

Kidney injury

• Acute kidney injury and worsening of chronic renal failure, which may sometimes require hemodialysis in patients treated with GLP-1 receptor agonists, has been described
• Most reported events occurred in patients who had experienced nausea, vomiting, diarrhea, or dehydration
• Events also reported in patients without known underlying renal disease
• Monitor renal function when initiating or escalating doses in patients reporting severe adverse GI reactions

Hypersensitivity

• Serious hypersensitivity reactions reported with GLP-1 receptor agonists; caution in patients with history of angioedema or anaphylaxis with a GLP-1 receptor agonist
• Unknown whether such patients will be predisposed to these reactions with tirzepatide
• If hypersensitivity reactions occur, discontinue treatment, treat promptly, and monitor until signs and symptoms resolve

Drug interaction overview

• Insulin secretagogues or insulin

  • May require dosage modification
  • Coadministration with insulin secretagogues (eg, sulfonylureas) or insulin may increase risk of hypoglycemia
  • Consider lower dose of secretagogue or insulin to reduce risk of hypoglycemia
  • Inform patients using concomitant medications of risk of hypoglycemia and educate them on signs and symptoms of hypoglycemia

• Oral drugs with narrow therapeutic index

  • Caution/dosage modification
  • Tirzepatide may delay gastric emptying, thereby potentially impacting oral absorption
  • Caution with drugs having a narrow therapeutic index (eg, warfarin)
  • Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or to add a barrier method of contraception for 4 weeks after initiation and for 4 weeks after each tirzepatide dose escalation

Refrigerate at 2-8ºC (36-46ºF)

If needed, each single-dose pen can be stored unrefrigerated at temperatures not to exceed 30ºC (86ºF) for up to 21 days

Do not freeze; do use if frozen

Protect from light